AI-Assisted Spirometry Interpretation in Primary Care: A Randomized Controlled Trial
Doe G. et al, (2025), NEJM AI, 2
Chronotherapy in asthma: BD or not BD? That is the question
Smallcombe N. and Russell RE., (2025), Thorax
Management and mechanisms of eosinophil action in asthma: mind the gap?
Russell REK., (2025), The Lancet. Respiratory medicine, 13, 190 - 191
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial
Ramakrishnan S. et al, (2025), The Lancet Respiratory Medicine, 13, 59 - 68
Results from a UK consensus about the optimal prescribing of medium strength triple therapy in uncontrolled adult asthma patients in the NHS
Russell REK. et al, (2024), Journal of Family Medicine and Primary Care, 13, 5885 - 5893
Exploring patients’ and carers’ experiences, understandings and expectations of COPD exacerbations:an interview study
Hutchinson A. et al, (2024), BJGP Open, BJGPO.2024.0026 - BJGPO.2024.0026
CORRECTION to: “Global mortality and readmission rates following COPD exacerbation-related hospitalisation: a meta-analysis of 65 945 individual patients” (ERJ Open Res 2024; 10: 00838-2023)
Waeijen-Smit K. et al, (2024), ERJ Open Research, 10
Clinical characteristics of chronic obstructive pulmonary disease patients with superoptimal peak inspiratory flow rate.
Kim T. et al, (2024), Scientific reports, 14
QRISK3 underestimates the risk of cardiovascular events in patients with COPD.
Amegadzie JE. et al, (2024), Thorax, 79, 718 - 724
Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19.
Cass SP. et al, (2024), ERJ open research, 10, 919 - 2023
Development and validation of a new algorithm for improved cardiovascular risk prediction
Hippisley-Cox J. et al, (2024), Nature Medicine, 30, 1440 - 1447
Accelerated immune ageing is associated with COVID-19 disease severity
Lord JM. et al, (2024), Immunity & Ageing, 21
Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.
Ramakrishnan S. et al, (2024), The Lancet. Respiratory medicine, 12, 67 - 77
Spirometry services in England post-pandemic and the potential role of AI support software: a qualitative study of challenges and opportunities
Doe G. et al, (2023), British Journal of General Practice, 73, e915 - e923
Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study
Jackson C. et al, (2023), The Lancet Respiratory Medicine, 11, 673 - 684
Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls
Zheng B. et al, (2023), The Lancet Regional Health - Europe, 29, 100635 - 100635
Inhaled corticosteroids for the treatment of COVID-19.
Bafadhel M. et al, (2022), European respiratory review : an official journal of the European Respiratory Society, 31